From June 11 to 14, 2026, the international hematology community met in Stockholm, Sweden, for the 31st Annual Meeting of the European Hematology Association (EHA) – one of the leading congresses in the field of hematology. The focus was on current advances in the diagnosis and treatment of hematological diseases, including innovative cellular therapies, immunotherapies, and new targeted approaches. Learn more here about the most important study data and clinically relevant findings on the indications of multiple myeloma and myelofibrosis – concisely summarized by our experts.
From June 11 to 14, 2026, the international hematology community met in Stockholm, Sweden, for the 31st Annual Meeting of the European Hematology Association (EHA) – one of the leading congresses in the field of hematology. The focus was on current advances in the diagnosis and treatment of hematological diseases, including innovative cellular therapies, immunotherapies, and new targeted approaches. Learn more here about the most important study data and clinically relevant findings on the indications of multiple myeloma and myelofibrosis – concisely summarized by our experts.
From June 11 to 14, 2026, the international hematology community met in Stockholm, Sweden, for the 31st Annual Meeting of the European Hematology Association (EHA) – one of the leading congresses in the field of hematology. The focus was on current advances in the diagnosis and treatment of hematological diseases, including innovative cellular therapies, immunotherapies, and new targeted approaches. Learn more here about the most important study data and clinically relevant findings on the indications of multiple myeloma and myelofibrosis – concisely summarized by our experts.
From June 11 to 14, 2026, the international hematology community met in Stockholm, Sweden, for the 31st Annual Meeting of the European Hematology Association (EHA) – one of the leading congresses in the field of hematology. The focus was on current advances in the diagnosis and treatment of hematological diseases, including innovative cellular therapies, immunotherapies, and new targeted approaches. Learn more here about the most important study data and clinically relevant findings on the indications of multiple myeloma and myelofibrosis – concisely summarized by our experts.
